B
Bengt Liljas
Researcher at AstraZeneca
Publications - 36
Citations - 2113
Bengt Liljas is an academic researcher from AstraZeneca. The author has contributed to research in topics: Budesonide & Cost effectiveness. The author has an hindex of 16, co-authored 30 publications receiving 2018 citations. Previous affiliations of Bengt Liljas include Lund University.
Papers
More filters
Journal ArticleDOI
Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report
Scott D. Ramsey,Richard J. Willke,Andrew Briggs,Ruth E. Brown,Martin Buxton,Anita Chawla,John R. Cook,Henry A. Glick,Bengt Liljas,Diana B. Petitti,Shelby D. Reed +10 more
TL;DR: Trial-based cost-effectiveness studies have appeal because of their high internal validity and timeliness and improving the quality and uniformity of these studies will increase their value to decision makers who consider evidence of economic value along with clinical efficacy when making resource allocation decisions.
Journal ArticleDOI
How to calculate indirect costs in economic evaluations.
TL;DR: Neither the friction-cost approach nor the QALY approach can be recommended over the more commonly used human capital- cost approach for estimating the indirect costs of a disease in economic evaluations from a societal perspective.
Journal ArticleDOI
An experimental comparison of dichotomous choice contingent valuation questions and real purchase decisions
TL;DR: In this article, the results of an experiment comparing the dichotomous choice (DC) contingentvaluation (CV) approach with real purchase decisions for a consumer good are reported.
Journal ArticleDOI
Experimental Results on Expressed Certainty and Hypothetical Bias in Contingent Valuation
TL;DR: In this paper, the authors carried out an experiment to compare the dichotomous choice contingent valuation method with real purchase decisions for a consumer good and confirmed previous findings that hypothetical yes responses overestimate real decision making.
Journal ArticleDOI
The demand for health with uncertainty and insurance.
TL;DR: This paper develops Michael Grossman's demand-for-health model by let the depreciation rate depend upon the level of health, by letting the incidence and size of illness be uncertain and by investigating how the individual's demand for health would be affected by the introduction of insurance.